Literature DB >> 2785585

Comparative biodistributions of yttrium- and indium-labeled monoclonal antibody B72.3 in athymic mice bearing human colon carcinoma xenografts.

M Roselli1, J Schlom, O A Gansow, A Raubitschek, S Mirzadeh, M W Brechbiel, D Colcher.   

Abstract

The biodistribution of yttrium- and indium-labeled monoclonal antibody (MAb) B72.3 IgG using three different chelate conjugates (SCN-Bz-EDTA, CA-DTPA, and SCN-Bz-DTPA) was compared in athymic mice bearing LS-174T tumors. The 88Y-SCN-Bz-DTPA-B72.3 yielded 40% ID/g at 5-7 days in the tumors, while the 88Y-SCN-Bz-EDTA-B72.3 and 88Y-CA-DTPA-B72.3 showed only 6-8% ID/g. The yttrium uptake in the bone with the SCN-Bz-EDTA and CA-DTPA conjugated IgG was over 14 and 11% ID/g, respectively, while 88Y-SCN-Bz-DTPA-B72.3 showed only 3% ID/g. In contrast, the 111In-labeled B72.3 uptake in the bone with all three chelate conjugates was 2-3% ID/g. The differences in yttrium- versus indium-labeled MAb biodistributions demonstrate the difficulty in using 111In-labeled MAbs to predict the biodistribution and dosimetry of 90Y-labeled MAbs unless chelate conjugates such as SCN-Bz-DTPA are used.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2785585

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  12 in total

Review 1.  Dosimetry of yttrium-labelled radiopharmaceuticals for internal therapy: 86Y or 90Y imaging?

Authors:  Stephan Walrand; Glenn D Flux; Mark W Konijnenberg; Roelf Valkema; Eric P Krenning; Renaud Lhommel; Stanislas Pauwels; Francois Jamar
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-03-11       Impact factor: 9.236

2.  Iodine-131 labelled octreotide: not an option for somatostatin receptor therapy.

Authors:  W H Bakker; W A Breeman; M E van der Pluijm; M de Jong; T J Visser; E P Krenning
Journal:  Eur J Nucl Med       Date:  1996-07

3.  Radioimmunoscintigraphy of colorectal cancer with technetium-99m-labeled murine anti-carcinoembryonic antigen monoclonal antibody in athymic nude mice.

Authors:  N Watanabe; N Oriuchi; S Sugiyama; M Kuroki; Y Matsuoka
Journal:  Ann Nucl Med       Date:  1994-02       Impact factor: 2.668

4.  Preclinical radioimmunotargeting of folate receptor alpha using the monoclonal antibody conjugate DOTA-MORAb-003.

Authors:  Peter M Smith-Jones; Neeta Pandit-Taskar; Wei Cao; Joseph O'Donoghue; Martin D Philips; Jorge Carrasquillo; Jason A Konner; Lloyd J Old; Steven M Larson
Journal:  Nucl Med Biol       Date:  2008-04       Impact factor: 2.408

5.  In vitro characterization of (177)Lu-radiolabelled chimeric anti-CD20 monoclonal antibody and a preliminary dosimetry study.

Authors:  Flavio Forrer; Jianhua Chen; Melpomeni Fani; Pia Powell; Andreas Lohri; Jan Müller-Brand; Gerhard Moldenhauer; Helmut R Maecke
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-04-07       Impact factor: 9.236

6.  In vitro and in vivo effects of diethylene triamine penta-acetic acid on the distribution of indium-111 monoclonal antibody metabolism.

Authors:  Y Kimura; T Fujii; K Ochi; A Akamune; K Hamamoto
Journal:  Eur J Nucl Med       Date:  1992

Review 7.  Problems of delivery of monoclonal antibodies. Pharmaceutical and pharmacokinetic solutions.

Authors:  R M Reilly; J Sandhu; T M Alvarez-Diez; S Gallinger; J Kirsh; H Stern
Journal:  Clin Pharmacokinet       Date:  1995-02       Impact factor: 6.447

Review 8.  Monoclonal antibodies in the management of carcinoma patients.

Authors:  M Roselli; C U Casciani; F Guadagni; O Buonomo; B Iorio; A Diodati; V Vittorini; J W Greiner; D Colcher; J Schlom
Journal:  Med Oncol Tumor Pharmacother       Date:  1991

9.  ImmunoPET: Concept, Design, and Applications.

Authors:  Weijun Wei; Zachary T Rosenkrans; Jianjun Liu; Gang Huang; Quan-Yong Luo; Weibo Cai
Journal:  Chem Rev       Date:  2020-03-23       Impact factor: 60.622

10.  Comparative biodistribution of indium- and yttrium-labeled B3 monoclonal antibody conjugated to either 2-(p-SCN-Bz)-6-methyl-DTPA (1B4M-DTPA) or 2-(p-SCN-Bz)-1,4,7,10-tetraazacyclododecane tetraacetic acid (2B-DOTA).

Authors:  L Camera; S Kinuya; K Garmestani; M W Brechbiel; C Wu; L H Pai; T J McMurry; O A Gansow; I Pastan; C H Paik
Journal:  Eur J Nucl Med       Date:  1994-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.